Skip to main content
. Author manuscript; available in PMC: 2011 Aug 5.
Published in final edited form as: World J Oncol. 2011 Apr;2(2):53–63. doi: 10.4021/wjon301w

Figure 3.

Figure 3

Western blotting for determination of Bax:Bcl-2 ratio in Ewing’s sarcoma SK-N-MC and RD-ES xenografts. Treatments for 8 or 15 days: CTL, 4-HPR (20 μg/kg/day), GST (2 mg/kg/day), and 4-HPR (20 μg/kg/day) plus 4-h later GST (2 mg/kg/day). (A) Representative Western blots (n ≥ 3) showed expression of 42 kD β-actin, 21 and 24 kD Bax, and 26 kD Bcl-2, and (B) changes in Bax:Bcl-2 ratio in SK-N-MC and RD-ES xenografts. Significant difference between CTL and a treatment was indicated by *P < 0.05 or **P < 0.001.